Jazz Pharmaceuticals, Inc. vs Eli Lilly & Co.
JAZZ vs LLY — side-by-side comparison from reported financials. JAZZ leads 4, LLY leads 7 of 11 comparable metrics.
Jazz Pharmaceuticals, Inc.
JAZZ · Healthcare
$218.42-1.81%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | JAZZ | LLY |
|---|---|---|
| Price | $218.42 | $1 177.20 |
| Market cap | $14.2B | $1.05T |
| Revenue (TTM) | $4.60B | $79.7B |
| Revenue growth | +5.3% | +31.7% |
| Net margin | 20.4% | 33.5% |
| Free cash flow | $1.59B | $18.2B |
| Net cash (debt) | ($2.94B) | ($35.2B) |
| 1-year price return | +58.1% | +37.6% |
| P/E | 15.1 | 41.6 |
| P/E vs own history (cheap-side %) | 90% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 21% | 93% |
| Altman Z-score | 2.13 | 7.10 |
| CV checks passed | 9 of 10 | 11 of 10 |
| Employees | 2,890 | 50,000 |
Full résumé-style profiles: JAZZ CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.